These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37545411)

  • 21. Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy.
    Qian L; Zhou C; Shen J; Cen J; Yin W
    Oncotarget; 2016 May; 7(18):25783-90. PubMed ID: 27029056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment Options for Recurrent Primary CNS Lymphoma.
    Kaulen LD; Baehring JM
    Curr Treat Options Oncol; 2022 Nov; 23(11):1548-1565. PubMed ID: 36205806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical Efficacy of High Dose Methotrexate, Temozolomide and Rituximab in the Treatment of Patients with Primary Central Nervous System Lymphoma].
    Pang DW; Chen FL; Guo HG; Jiang XM; Wei XJ; Liu SC; Huang L; Liang ZL; Li WY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1175-1180. PubMed ID: 34362499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab, Methotrexate, Carmustine, Etoposide, and Prednisone (RMBVP) for the treatment of relapsed/refractory primary central nervous system lymphoma: a retrospective single-center study.
    Reiss SN; Yerram P; Modelevsky L; Grommes C
    Leuk Lymphoma; 2022 Mar; 63(3):627-632. PubMed ID: 34758711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
    Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y
    Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).
    Rubenstein JL; Hsi ED; Johnson JL; Jung SH; Nakashima MO; Grant B; Cheson BD; Kaplan LD
    J Clin Oncol; 2013 Sep; 31(25):3061-8. PubMed ID: 23569323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.
    Wieduwilt MJ; Valles F; Issa S; Behler CM; Hwang J; McDermott M; Treseler P; O'Brien J; Shuman MA; Cha S; Damon LE; Rubenstein JL
    Clin Cancer Res; 2012 Feb; 18(4):1146-55. PubMed ID: 22228634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma.
    Zhao D; Qian L; Shen J; Liu X; Mei K; Cen J; Wang Y; Li C; Ma Y
    J Cell Mol Med; 2014 Jun; 18(6):1081-6. PubMed ID: 24628986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse.
    Du P; Chen H; Shen L; Liu X; Wu X; Chen L; Cao A; Geng D
    Curr Oncol; 2022 Sep; 29(9):6642-6656. PubMed ID: 36135091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose cytarabine salvage therapy for recurrent primary CNS lymphoma.
    Chamberlain MC
    J Neurooncol; 2016 Feb; 126(3):545-50. PubMed ID: 26563190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary Central Nervous System Lymphoma: Clinical Characteristics, Treatment Options and Therapeutic Outcome in 36 Patients. A Single Center Experience.
    Zektser M; Rabinovich A; Grinbaum U; Porges T; Gozlan A; Gourevitch A; Al-Athamen K; Barrett O; Peles I; Kaisman-Elbaz T; Levi E
    Isr Med Assoc J; 2022 Oct; 24(10):654-660. PubMed ID: 36309861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic management of refractory or relapsed primary central nervous system lymphomas.
    Reni M; Ferreri AJ
    Ann Hematol; 2001; 80 Suppl 3():B113-7. PubMed ID: 11757691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome of patients with newly diagnosed primary CNS lymphoma after high-dose methotrexate followed by consolidation whole-brain radiotherapy and cytarabine: an 8-year cohort study.
    Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Rattarittamrong E; Tantiworawit A; Norasetthada L
    Int J Clin Oncol; 2021 Oct; 26(10):1805-1811. PubMed ID: 34236556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R-Mini-CYVE) regimen for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma not eligible for intensive chemotherapy.
    Abdayem P; Ibrahim N; El Dakdouki Y; Willekens C; Ghez D; A Rouche J; Dartigues P; Desmaris R; Danu A; Rossignol J; Lazarovici J; Fermé C; Ribrag V; Michot JM
    Eur J Haematol; 2021 Apr; 106(4):574-583. PubMed ID: 33512026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.
    Erbe AK; Wang W; Carmichael L; Hoefges A; Grzywacz B; Reville PK; Ranheim EA; Hank JA; Kim K; Seo S; Mendonca EA; Song Y; Kenkre VP; Hong F; Gascoyne RD; Paietta E; Horning SJ; Miller JS; Kahl B; Sondel PM
    J Immunother Cancer; 2019 Mar; 7(1):70. PubMed ID: 30871628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation.
    Cohen YI; Lebel E; Zimran E; Shaulov A; Stepensky P; Grisariu S; Avni B
    Transplant Cell Ther; 2023 Aug; 29(8):505.e1-505.e8. PubMed ID: 37160229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.
    Patel MP; Kirkpatrick JP; Johnson MO; Healy P; Herndon JE; Lipp ES; Miller ES; Desjardins A; Randazzo D; Friedman HS; Ashley DM; Peters KB
    J Neurooncol; 2020 Apr; 147(2):477-483. PubMed ID: 32140975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A single centre study of the treatment of relapsed primary central nervous system lymphoma (PCNSL) with single agent temozolomide.
    Wong SF; Gan HK; Cher L
    J Clin Neurosci; 2012 Nov; 19(11):1501-5. PubMed ID: 22995759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.